| |
 |
|
Henderson Morley plc
is a
biotechnology company publicly traded on the London Stock
Exchange (AIM). The company is developing an exciting
pipeline of anti-viral drugs and vaccines and biological
products to fight a wide range of diseases in humans and
animals.
From the corporate headquarters in Birmingham UK, several
important discoveries have been made. These are now being
developed to fulfill their company vision of improving
human and animal health. These products are targeted at
diseases that currently lack adequate treatment, or where
existing vaccines are either unavailable or are
ineffective.
Henderson Morley has a broad pipeline of clinical and
pre-clinical candidates in a wide range of disease areas
including |
-
Skin warts
-
Verrucae (warts on the feet and toes)
-
Herpes simplex infections of the mouth
and genitalia, and eyes
-
Adenovirus infection of the eyes
-
Orphan diseases including recurrent
respiratory papillomatosis (RRP)
-
Treatments for feline herpes (in cats)
|
|
The company also has a comprehensive
vaccine development programme targeted at viruses which
include, but are not limited to; |
-
Herpes simplex
-
Cytomegalovirus
-
Koi Herpes virus
The technology is also being developed
as an immunotherapy for various forms of Cancer.
The company is also developing |
|
|
|
|
To send a message directly to Henderson
Morley plc,
please use this form, where you may also
optionally register an interest in taking part in clinical
trials of new products.
Henderson Morley plc
Metropolitan House
2 Salisbury Road
Moseley
Birmingham B13 8JS
Tel +44 (0) 121 442 4600
Fax +44 (0) 121 442 4611
info@henderson-morley.com
|
| |
|
 |
|
For the latest corporate announcements,
please see the
Investor relations page.
Bishopsgate Communications
2nd Floor
Henry Thomas House
5-11 Worship Street
London EC2A 2BH
Tel 0207 562 3350
Fax 0207 628 0889
investors@henderson-morley.com |
|
|
